20/04/2014 19:36:08 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
04/14/20148:00AMBWBristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with ...
Atazanavir sulfate capsules are available as Reyataz® Bristol-Myers Squibb Company (NYSE:BMY) announced today the submission of a new drug application (NDA) on April 4, 2014 to the U.S. Food and Drug Administration (FDA) for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz®, and... More...>>
04/10/20149:44AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Thursday's session are Bed Bath & Beyond Inc. (BBBY), Rite Aid Corp. (RAD) and EBay Inc. (EBAY). Bed Bath & Beyond's fiscal fourth-quarter earnings fell 11% as the home-furnishings retailer recorded a drop in sales. Shares fell 5.2% to $64.35 premarket... More...>>
04/10/20149:43AMDJNMerck: Hepatitis C Drug Shows 98% Cure Rate in Mid-Stage Trial -- Update
By Michael Calia Merck & Co. said Thursday that a pair of its hepatitis C virus treatments showed a cure rate of 98% in a mid-stage trial, supporting advancement of the study. The drug maker said it has initiated a Phase 3 trial after analyzing the study results of the 12-week regimen using the oral treatment, which... More...>>
04/10/20147:05AMPRNCABristol-Myers Squibb présente les données d'une étude de Phase III demontrant que le traitment experimental de combinaison...
Bristol-Myers Squibb présente les données d'une étude de Phase III demontrant que le traitment experimental de combinaison orale daclatasvir/asunaprévir produit des taux de réponse virale soutenue (RVS(12)) jusqu'à 90 % chez un vaste éventail de patients atteints d'hépatite... More...>>
04/10/20147:05AMPRNCABristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy ...
Bristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR(12) rates of up to 90% among broad range of genotype 1b hepatitis C patients Canada NewsWire MONTREAL, April 10, 2014 Results of the HALLMARK-Dual study include data among genotype 1b... More...>>
04/10/20147:00AMBWBristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir & Asunaprevir Therapy Ac...
Results of the HALLMARK-Dual study include data among genotype 1b cirrhotic and non-cirrhotic, treatment-naïve, non-responder, and peginterferon/ribavirin ineligible and intolerant patients Study reinforces the potential of daclatasvir-based regimens to treat HCV patients with high unmet needs Data to be presented during... More...>>
04/09/20148:00AMPRNUSUpcoming Results and Conference Call Schedules, New Office Facility, and Stock Price Movements-Analyst Notes on Biogen, Actav...
Upcoming Results and Conference Call Schedules, New Office Facility, and Stock Price Movements-Analyst Notes on Biogen, Actavis, Bristol-Myers, AbbVie, and Baxter Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, April 9, 2014 NEW YORK, April 9, 2014 /PRNewswire/ -- Today... More...>>
04/08/20148:00AMPRNUSEarnings Release Schedules, Product Portfolio Expansion, Initiatives and Stock Price Movements - Analyst Notes on Biogen Idec...
Earnings Release Schedules, Product Portfolio Expansion, Initiatives and Stock Price Movements - Analyst Notes on Biogen Idec, Bristol-Myers, Regeneron Pharma, Illumina, West Pharma Services Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, April 8, 2014 NEW YORK, April... More...>>
04/08/20145:07AMPRNUSEuropean Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb's Partnering for Cure™ Virology Research Pr...
European Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb's Partnering for Cure™ Virology Research Programme PR Newswire PARIS, April 8, 2014 PARIS, April 8, 2014 /PRNewswire/ -- Partnering for Cure is Bristol-Myers Squibb's flagship, Pan-European scientific initiative supporting breakthrough research... More...>>
04/07/201412:34PMPRNUSTechnical Pointers on Pharmaceuticals Equities -- Research on Merck, Bristol-Myers Squibb, Johnson & Johnson, and Eli Lilly
Technical Pointers on Pharmaceuticals Equities -- Research on Merck, Bristol-Myers Squibb, Johnson & Johnson, and Eli Lilly Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, April 7, 2014 LONDON, April 7, 2014 /PRNewswire/ -- On Friday, April 04, 2014, the NASDAQ Composite... More...>>
04/07/20148:00AMBWBristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis C
U.S. application submission marks third major daclatasvir regulatory milestone globally, follows E.U. and Japan Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have submitted new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for the investigational products daclatasvir (DCV... More...>>
04/01/20149:00AMBWBristol-Myers Squibb to Announce Results for First Quarter 2014 on April 29
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2014 on Tuesday, April 29, 2014. During a conference call at 9 a.m. EDT on April 29, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public are invited... More...>>
03/27/201411:00AMZACKSBristol Myers Deal Overshadows Q4 loss at Five Prime - Analyst Blog
Five Prime Therapeutics, Inc. (FPRX) has been in the news over the past few days. Investors at Five Prime, which went public in September last year, had plenty to cheer when the company inked a $350 million deal with Bristol-Myers Squibb Company (BMY) earlier in the month. Five Prime Therapeutics saw it shares soar 22.6... More...>>
03/27/20148:14AMBWIn A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvul...
Blood Pressure Control Key Factor in Stroke Risk Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial that assessed the effect of blood pressure control on outcomes as well as the treatment effect of Eliquis (apixaban... More...>>
03/24/20145:39AMBWBristol-Myers Squibb to Present Data for Daclatasvir in Multiple Investigational All-oral Combinations across Hepatitis C Gen...
Daclatasvir data demonstrates potential to address high unmet needs, including cirrhotic and treatment-experienced patients, and those with genotypes 1, 2, 3 and 4 Breadth of viral hepatitis data underscores Company’s commitment to advancing research of liver diseases Bristol-Myers Squibb Company (NYSE:BMY) announced... More...>>
03/21/20148:00AMPRNUSFDA Approvals, Financial Highlights, Restated Treatment Indications, and Updates on Product Pipelines - Analyst Notes on Bris...
FDA Approvals, Financial Highlights, Restated Treatment Indications, and Updates on Product Pipelines - Analyst Notes on Bristol-Myers Squibb, Galena, Teleflex, GW Pharmaceuticals, and CytRx Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, March 21, 2014 NEW YORK, March... More...>>
03/19/201412:02PMDJNAlder Biopharmaceuticals Files for IPO of Up to $115 Million
By Michael Calia Alder Biopharmaceuticals Inc. filed for an initial public offering of up to $115 million in common stock, as the company looks to fund product development. The company said it seeks to commercialize therapeutic antibodies. Its pipeline includes two internally discovered antibodies--one wholly owned, one... More...>>
03/19/20148:00AMPRNUSHealth Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly
Health Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, March 19, 2014 LONDON, March 19, 2014 /PRNewswire/ -- On Tuesday, March 18, 2014, the NASDAQ Composite finished... More...>>
03/18/201412:00PMZACKSBristol-Myers, Five Prime Join Forces, Shares up - Analyst Blog
In a bid to strengthen its oncology pipeline, Bristol-Myers Squibb Company (BMY) joined forces with Five Prime Therapeutics, Inc. (FPRX). The oncology deal grants Bristol-Myers access to Five Prime’s immuno-oncology platform. Bristol-Myers is also responsible for identifying the most promising candidates which will... More...>>
03/17/20149:37AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Monday's session are Keurig Green Mountain Inc. (GMCR) and JA Solar Holdings Co. (JASO). S&P Dow Jones Indices said Friday it will add Keurig Green Mountain Inc. (GMCR) to its S&P 500 index, one of a handful of index changes announced Friday. Shares... More...>>


NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy140420 19:36